Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding

Taavi Päll, Annica Gad, Lagle Kasak, Monika Drews, Staffan Strömblad, Priit Kogerman
  • Oncogene, September 2004, Nature Publishing Group
  • DOI: 10.1038/sj.onc.1208083
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Professor Staffan Strömblad